Clinical trial · Observational
Multidisciplinary Follow-up of Patients Treated for Malignant Hematological Disease
Multidisciplinary Follow-up of Patients Treated for Malignant Hematological Disease; Focus on the Patient's Preferences and Life Situation
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to adjust and test an existing internet-based tool for collecting patient-reported outcome measures and to use the internet-based tool in an multidisciplinary follow-up of patients treated for malignant hematological diseases. The patient-reported outcome measurements will be used in describing the patients' health-related quality of life (HRQoL) and to investigate whether the HRQol will increase due to participation in multidisciplinary follow-up.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Hematologic Neoplasm | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Health-Related Quality of Life (HRQoL) - General
- timeFrame
- HRQoL is assessed every 2, 3, 4 or 6 months, up to 18 months.
- description
- Patients will be asked to electronically fill out questionnaires before each consultation. The questionnaire that will be used to measure HRQoL is SF-36. SF-36 is a generic questionnaire which can be used to assess HRQoL in the general public.
- measure
- Health-Related Quality of Life (HRQoL) - Disease specific
- timeFrame
- HRQoL is assessed every 2, 3, 4 or 6 months, up to 18 months.
- description
- Patients will be asked to electronically fill out questionnaires before each consultation. The questionnaire that will be used to measure HRQoL is EORTC C30 QLQ. EORTC C30 QLQ is a disease specific questionnaire which can be used to assess HRQoL in patients diagnosed with cancer
Secondary outcomes (2)
- measure
- Symptoms of depression and anxiety
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * patients diagnosed with malignant hematological disease; Morbus Hodgkin and B- and T-cell disease * patients followed before or after 1. line treatment * patients in stable phase \> 6 months after 1. line treatment * the patients participation in the study must be assessed and decided by the doctor responsible for the patient's course of treatment Exclusion Criteria: * Health conditions which demands close medical monitoring * conditions which compromise the ability to understand the study and submit informed consent (ex.: dementia and severe mental illness / disability) * lack of capability to fill out electronic questionnaires * poor self-care and/or compliance
References
Publications (0)
Data not yet available